Sydney, Australia, Monday, 30 January 2023: Next Science Limited (ASX:NXS) (Next Science/Company) today announced its Appendix 4C Quarterly Cash Flow Report for the period 1 October 2022 to 31 December 2022 (Q4).
In accordance with ASX Listing Rule 4.7C, set out below is a summary of Next Science’s key activities during Q4 and subsequent to Q4. Further details are provided in the investor presentation released separately.
Activity Summary:
-- Full year revenue (unaudited) US$11.7M, 31% increase on prior year
-- Full year product revenue (unaudited) US$11.3M, 40% increase on prior year
-- Q4 cash receipts from customers US$2.9M
-- New DME business unit launched in October, with encouraging performance in November and December and 150 prescribers using the service as at January 2023
-- Cash in the bank US$5.1M
-- Net Cash Burn for the Quarter US$2.9M
-- Payments to Directors US$163K
For more information, download the attached PDF.
Download this document
